Business Information
The group's principal activity is to develop and commercialize products and technologies for diagnostic imaging and ethical drug development. The group uses peptide, monoclonal antibody and radiopharmaceutical technologies for imaging, diagnosing and treating infections. The main products of the group are metal ion-induced distinctive array of structures (midas), pt-141 and leutech. Midas is useful for developing drugs to treat diseases or for diagnostic imaging. Pt-141 is a peptide hormone product for the treatment of sexual dysfunction. Leutech, a diagnostic imaging product is used to image and locate the site of infection or inflammation within the body. The group operates solely in the domestic market.
|
|
Name |
Title
|
Email
|
| John Prendergast | Chmn. | N/A | | Stephen Wills | CFO, Exec. VP - Operations, Sec., Treasurer | N/A | | Trevor Hallam | Exec. VP - Research, Development | N/A | | Carl Spana | Dir., CEO, Pres. | N/A | | Christopher Steidle | Member - Scientific Advisory Board | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 19,749 | (28,959) | | 2005 | 17,957 | (14,358) | | 2004 | 2,315 | (26,318)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
